Vergote I - Search Results

1

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.

Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, Carbonez A, Van Huffel S, Ameye L, Paridaens R. Morales L, et al. Among authors: vergote i. Anticancer Drugs. 2004 Sep;15(8):753-60. doi: 10.1097/00001813-200409000-00003. Anticancer Drugs. 2004. PMID: 15494636 Clinical Trial.

2

Case report: mixed germ cell tumour of the ovary presenting as a missed abortion.

Vergote IB, Witters I, Moerman P, Timmerman D, Spitz B, Van Assche FA. Vergote IB, et al. Eur J Gynaecol Oncol. 1996;17(6):518-9. Eur J Gynaecol Oncol. 1996. PMID: 8971532 No abstract available.

3

The diagnostic problem of endometrial stromal sarcoma: report on six cases.

Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I. Amant F, et al. Among authors: vergote i. Gynecol Oncol. 2003 Jul;90(1):37-43. doi: 10.1016/s0090-8258(03)00207-5. Gynecol Oncol. 2003. PMID: 12821339 Review.

4

Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women.

Timmerman D, Neven P, Deprest J, Konstantinović ML, Vergote I. Timmerman D, et al. Among authors: vergote i. Cancer. 2003 Jul 15;98(2):431-2; author reply 432-3. doi: 10.1002/cncr.11499. Cancer. 2003. PMID: 12872366 Free article. No abstract available.

5

The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.

Buzdar AU, Vergote I, Sainsbury R. Buzdar AU, et al. Among authors: vergote i. Breast J. 2004 May-Jun;10(3):211-7. doi: 10.1111/j.1075-122X.2004.21320.x. Breast J. 2004. PMID: 15125747

6

Endometriosis and the development of malignant tumours of the pelvis. A review of literature.

Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Van Gorp T, et al. Among authors: vergote i. Best Pract Res Clin Obstet Gynaecol. 2004 Apr;18(2):349-71. doi: 10.1016/j.bpobgyn.2003.03.001. Best Pract Res Clin Obstet Gynaecol. 2004. PMID: 15157647 Review.

7

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Christiaens MR, Vergote I. Huang HJ, et al. Among authors: vergote i. Breast Cancer Res Treat. 2005 May;91(1):81-7. doi: 10.1007/s10549-004-8235-8. Breast Cancer Res Treat. 2005. PMID: 15868434

8

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Howell A, et al. Among authors: vergote i. Cancer. 2005 Jul 15;104(2):236-9. doi: 10.1002/cncr.21163. Cancer. 2005. PMID: 15937908 Free article. Clinical Trial.

9

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.

Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, Van Robaeys J, Neven P, Moerman P, Vergote I. Amant F, et al. Among authors: vergote i. Gynecol Oncol. 2005 Aug;98(2):274-80. doi: 10.1016/j.ygyno.2005.04.027. Gynecol Oncol. 2005. PMID: 15972232

10

Endometrial cancer.

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Amant F, et al. Among authors: vergote i. Lancet. 2005 Aug 6-12;366(9484):491-505. doi: 10.1016/S0140-6736(05)67063-8. Lancet. 2005. PMID: 16084259 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

886 results

Search Page

Filters